5:47 PM
 | 
Feb 14, 2013
 |  BC Extra  |  Company News

FDA accepts oral treprostinil resubmission

United Therapeutics Corp. (NASDAQ:UTHR) said FDA accepted for review a resubmitted NDA for oral treprostinil to treat pulmonary arterial hypertension (PAH). The agency designated the NDA a Class 1 resubmission, with a March 31 PDUFA date. FDA...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >